SLU-PP-332 Half-Life: How Long It Stays in Your System
How long SLU-PP-332 stays in the body, how that shapes dosing frequency, and what is known about drug testing.
- Half-life
- Not found
- No published half-life found (PubMed search, 11 Oct 2026)
- Dosing interval
- Not reported
- Not stated in study abstracts (PubMed search, 11 Oct 2026)
- WADA
- Unclear
- Not named on the 2026 list
- Detection window
- Not found
- None reported as of 2 Oct 2026
SLU-PP-332 half-life
Half-life: no published half-life found (PubMed search, 11 Oct 2026). A half-life depends on the route (under the skin, into a vein, by mouth or nasal spray), so we report it per route with the study it came from.
What half-life means
Half-life is the time it takes for the amount of a drug in the blood to fall by half. After one half-life, about 50% is left; after two, about 25%; after four to five, only a few percent remain.
- A long half-life lets a drug be dosed less often, for example once a week.
- A short half-life means levels rise and fall quickly, which is why some peptides are given daily or more often.
- Effects can outlast blood levels, so half-life alone does not tell you how long a drug works.
What it means for dosing frequency
Study dosing intervals for SLU-PP-332: not stated in the study abstracts we summarise (PubMed search, 11 Oct 2026). Changing the interval changes how much drug builds up between doses, so it is not a free choice.
Drug tests and sport
WADA status unclearSLU-PP-332 is not named. S4.4 lists AMPK activators, PPAR-delta agonists and Rev-erb agonists; SLU-PP-332 is an ERR agonist, which the list does not mention. This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance.
Anti-doping labs use tests built for specific substances. Whether a given test detects SLU-PP-332, and for how long, is not reported in the anti-doping literature we checked (as of 2 Oct 2026).
What the mouse work says
The mouse study that introduced SLU-PP-332 says only that it has sufficient pharmacokinetic properties to be used as an in vivo chemical tool; the abstract gives no half-life.[5]
A medicinal-chemistry paper on analogues of SLU-PP-332, using cell assays and computer modelling, reports several with improved ligand efficiency, solubility or metabolic stability.[6]
What it is, and what is missing
Drugs@FDA returns no SLU-PP-332 product, so there is no label to cite for human pharmacokinetics.[7]
A full-text search of WADA's current list, recorded in the cached copy, found no occurrence of SLU-PP.[1]
Common questions
How long does SLU-PP-332 stay in your system?
We found no published half-life for SLU-PP-332 (PubMed search, 11 Oct 2026). As a rule, most of a dose is cleared after about four to five half-lives.
What is the half-life of SLU-PP-332?
No half-life is cited here. The mouse paper says only that the compound's pharmacokinetic properties suffice for use as an in vivo tool.[5]
Is SLU-PP-332 on the WADA prohibited list?
It is unclear. SLU-PP-332 is not named. S4.4 lists AMPK activators, PPAR-delta agonists and Rev-erb agonists; SLU-PP-332 is an ERR agonist, which the list does not mention. This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance.
Is SLU-PP-332 on the WADA list?
It is not named. The cached copy of the list records a full-text search that found no occurrence of SLU-PP.[1]
More on SLU-PP-332
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2PubMed search: "SLU-PP-332"[tiab] (10 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 3PubMed search: SLU-PP-332[tiab] OR SLU-PP-915[tiab] OR "ERR agonist"[tiab] AND exercise mimetic[tiab] (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 4PubMed search: ("SLU-PP-332"[tiab] OR "SLU-PP-915"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 5Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.ACS chemical biology · 2023PMID 36988910Accessed 2 Oct 2026
- 6Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling.International journal of biological macromolecules · 2026PMID 41850449Accessed 2 Oct 2026
- 7Drugs@FDA (openFDA) search: active ingredient "SLU-PP-332"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.